|
Jun 10
|
FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment
|
|
Jun 9
|
FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease
|
|
Jan 13
|
BIIB, ZTS, EXAS: Which “Strong Buy” Healthcare Stock is Best?
|
|
Jan 11
|
Is Eli Lilly Stock A Buy As It Battles In Obesity Drugs With A New Direct-To-Consumer Website?
|
|
Jan 11
|
EU regulators to consult advisers in review of Eisai Alzheimer’s drug
|